Caredx reports inducement grant under nasdaq listing rule 5635(c)(4)

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on april 15, 2024, caredx granted an option to purchase 700,706 shares of caredx's common stock (the “inducement option”) and 487,804 restricted stock units (the “inducement rsus” ) to.
CDNA Ratings Summary
CDNA Quant Ranking